Eden Research (EDEN)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

3.05p
   
  • Change Today:
    -0.18p
  • 52 Week High: 5.13
  • 52 Week Low: 3.00
  • Currency: UK Pounds
  • Shares Issued: 533.35m
  • Volume: 976,045
  • Market Cap: £16.27m

Eden Research gets approval for Novellus+ in Mexico

By Josh White

Date: Friday 20 Dec 2024

LONDON (ShareCast) - (Sharecast News) - Biopesticides and biocontrol products developer Eden Research announced on Friday that it has received regulatory approval in Mexico for 'Novellus+', an enhanced version of its flagship fungicide 'Mevalone'.
The AIM-traded firm said the product was approved for use against botrytis on a wide range of horticultural crops, including grapes, tomatoes, strawberries, and peppers, among other high-value fruits and vegetables.

It said the distribution of Novellus+ in Mexico would be managed exclusively by Advan Mexico, a subsidiary of Sipcam Oxon and one of the country's largest agrochemical input providers.

Advan's network of farmers would reportedly position Novellus+ to gain significant market traction in Mexico's diverse agricultural sector.

The approval was Eden's second regulatory success in Mexico, following the approval of its bionematicide 'Cedroz' in 2019.

Eden said the addition of Novellus+ was expected to contribute meaningfully to its revenue in the coming seasons, reflecting growing demand for sustainable agricultural solutions.

The company noted that Mexico, one of the world's top 15 economies, is a major exporter of agricultural products, particularly to the United States.

Its agricultural sector faced stringent cross-border standards, emphasising the need for residue-free produce.

Exports of berries, tomatoes, and peppers to the US alone totaled about $7.6bn in 2022.

"Given the significance of Mexico's agricultural exports, the approval for Novellus+ in Mexico marks an important milestone for the company as we continue to grow our product sales across North America," said chief executive officer Sean Smith.

"Critically, this latest approval includes an extensive range of crops which means that we are able to take advantage of the diverse nature of Mexico's agricultural market as well as its standing as one of the world's largest crop producing nations.

"This is also an exciting development as Novellus+ represents an evolution of Mevalone, allowing improved rates in the field, high levels of efficacy and a broader list of targets, all contributing to a larger addressable market in select territories."

Smith said registration efforts were also "well underway" in several additional countries, with the company "looking forward" to providing further updates on the growth of Novellus+ within its portfolio.

"We believe that the sustainability and efficacy of Novellus+ will stand our product apart in a growing market, particularly as local regulations increasingly demand strict control of pesticide residues on fruit and vegetables in order to meet consumer expectations and international standards."

At 0937 GMT, shares in Eden Research were up 0.13% at 3.86p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Eden Research Market Data

Currency UK Pounds
Share Price 3.05p
Change Today -0.18p
% Change -5.43 %
52 Week High 5.13
52 Week Low 3.00
Volume 976,045
Shares Issued 533.35m
Market Cap £16.27m

Eden Research Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
7.3% below the market average7.3% below the market average7.3% below the market average7.3% below the market average7.3% below the market average
10.64% below the sector average10.64% below the sector average10.64% below the sector average10.64% below the sector average10.64% below the sector average
Price Trend
57.8% below the market average57.8% below the market average57.8% below the market average57.8% below the market average57.8% below the market average
10.2% below the sector average10.2% below the sector average10.2% below the sector average10.2% below the sector average10.2% below the sector average
Income Not Available
Growth
53.40% above the market average53.40% above the market average53.40% above the market average53.40% above the market average53.40% above the market average
37.50% above the sector average37.50% above the sector average37.50% above the sector average37.50% above the sector average37.50% above the sector average

Eden Research Dividends

No dividends found

Trades for 13-Mar-2025

Time Volume / Share Price
16:12 72,166 @ 3.03p
15:28 305 @ 3.10p
11:17 400,000 @ 3.08p
11:11 400,000 @ 3.08p
10:54 8,000 @ 3.00p

Eden Research Key Personnel

CFO Alexander John Abrey
CEO Sean M. Smith

Top of Page